

Figure 3: Prioritization of main stakeholder groups by anticipated impact

<p>High priority systemic influence with direct impact on trials outcome selection</p>	<p>Medium priority systemic influence not specific to trials outcome selection</p>	<p>Lower priority individual/group influence</p>
<p>Funding bodies Value-framework/HTA organizations Regulatory bodies Pharmaceutical industry Trial registries Trial reporting guideline groups</p>	<p>Clinical guideline development groups Journals Patient groups SR/NMA reporting guideline groups Other COS groups</p>	<p>Trialists and trial staff SR/NMA researchers Academic organizations Medical Societies Health care providers CAT groups Shared decision-making programs</p>

CAT – Critically Appraised Topics; COS – core outcome set; HTA - health technology assessment; NMA - network meta-analysis; SR - systematic review;